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Introduction: This prospective, open-label, non-randomized, multi-
institutional phase II study was undertaken to assess the antitumor
activity and safety of docosahexaenoic acid–paclitaxel (Taxoprexin)
as first-line treatment of patients with advanced non-small cell lung
cancer.
Patients and Methods: Chemotherapy-naive patients were eligible
if they had measurable stage IIIB or IV non-small cell lung cancer.
Forty-four patients received docosahexaenoic acid–paclitaxel by
intravenous infusion every 21 days. Two doses were evaluated: 1100
mg/m2 and 900 mg/m2. Patients were monitored for toxicity and
tumor response.
Results: Patients received between one and seven (median, two) cycles
of treatment. Twenty-eight courses were administered in the cohort
starting at 1100 mg/m2 and 109 courses at 900 mg/m2. The starting
dose was reduced to 900 mg/m2 because of toxicity in the first 13
patients. Subsequently, the most severe toxicity was neutropenia
(grade III/IV in 68% of patients treated with 900 mg/m2). Forty
patients were eligible for assessment of tumor response. Two partial
responses (4.5%) were documented, and a further 16 patients
(36.4%) had stable disease based on an intent-to-treat analysis. The
median duration of survival for all patients was 243 days (range,
154–359) and the 1-year survival rate was 35%.
Conclusion: As a single-agent, docosahexaenoic acid–paclitaxel has
little activity in patients with advanced non-small cell lung cancer,
with 18 patients (40.1%) achieving either stable disease or a partial
response after treatment. Despite the low objective response rate,
treatment was associated with survival comparable to that seen with
standard platinum-based combination chemotherapy. The dose-lim-
iting toxicity was myelosuppression.
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Lung cancer is the single greatest cause of death frommalignancy in both men and women. Approximately 80%
of cases are non-small cell lung cancer (NSCLC) with most
patients presenting with locally advanced or metastatic dis-
ease, which is associated with a poor prognosis. The median
survival is only 4 to 6 months in untreated disease, and
palliative chemotherapy is the standard treatment for patients
of good performance status based on evidence from meta-
analyses confirming a modest survival advantage for ad-
vanced disease1 including elderly patients.2 Quality of life
also appears to improve with cytotoxic treatment.3–5 Identi-
fying an outpatient treatment regimen that maximizes quality
of life and prolongs survival while minimizing treatment-
related side effects is important, particularly in a group of
patients who have poorer performance status. Two-drug com-
binations, usually including a platinum-based agent, are con-
sidered to be efficacious regimens,6,7 although single-agent
therapy may be better tolerated.8,9 There is no convincing
evidence of the most effective regimen in this disease.10
The taxanes docetaxel and paclitaxel have efficacy as
first- or second-line therapy of advanced NSCLC.11,12 Both
are microtubule-stabilizing agents that promote microtubule as-
sembly and render them resistant to depolymerization. Because
microtubules are an essential component in cell division, cells
exposed to taxanes are arrested in the premitotic G2 phase and
therefore fail to divide. Response rates of up to 38% have been
reported after the use of single-agent taxanes in advanced pre-
viously untreated disease.12–15 Subsequent prospective, random-
ized data also suggest that taxanes improve survival and quality
of life in patients previously treated with chemotherapy.16,17
Taxanes are, however, associated with significant toxicity, in-
cluding myelosuppression, peripheral neuropathy, stomatitis,
and alopecia.
Design of new cytotoxic agents aims to maximize anti-
cancer effects by targeting the tumor preferentially to normal
tissue. Docosahexaenoic acid (DHA)–paclitaxel is a novel semi-
synthetic taxane with no cytotoxic activity until metabolized to
*Cancer Research UK Oxford Cancer Centre, Oxford, UK; †Guy’s Hospital,
London, UK; ‡Beatson Oncology Centre, Glasgow, UK; §Christie Hos-
pital NHS Trust, Manchester, UK; PhaseN Consulting, Wilmington, DE;
¶Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford,
UK.
Address for correspondence: Dennis Talbot, BSc, MB, BChir, MA, PhD,
FRCP, Cancer Research UK Oxford Cancer Centre, OX3 7LJ, UK.
E-mail: denis.talbot@cancer.org.uk
Copyright © 2006 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/06/0109-0984
Journal of Thoracic Oncology • Volume 1, Number 9, November 2006984
paclitaxel. It is a 2=-O-acyl conjugate of paclitaxel covalently
bound to the essential natural fatty acid DHA via an ester bond.
DHA is a prevalent fatty acid, essential for normal human
development and approved for exogenous administration by the
European regulatory authorities and the World Health Organi-
zation. Preclinical perfusion models support the theory that
tumors take up fatty acids, such as DHA, more avidly than
nonmalignant cells,18,19 allowing some degree of targeting of
neoplastic tissues. The inert prodrug DHA-paclitaxel conjugate
accumulates in tumor tissue where it is cleaved to paclitaxel.
Comparison of the pharmacokinetics of paclitaxel with conju-
gated DHA-paclitaxel, using a mouse model, also favors this
explanation. Equitoxic or equimolar doses of DHA-paclitaxel
resulted in significantly greater intratumor concentrations of
paclitaxel and a larger cytotoxic effect than paclitaxel alone.20
The unique pharmacokinetics profile may also partly be ex-
plained by extensive binding to plasma proteins.21 Preclinical
animal studies have suggested that DHA-paclitaxel may have an
improved therapeutic ratio when compared to paclitaxel,20,22 and
an early clinical trial suggested a more favorable toxicity pro-
file.23 Additionally, it can be given as an infusion on an outpa-
tient basis. This formed the strategic justification for evaluating
DHA-paclitaxel in the clinical setting in NSCLC. We report a
nonrandomized, prospective, open-label phase II multicenter
trial. The primary aim was to assess the antitumor activity and
toxicity of DHA-paclitaxel as first-line treatment for stage IIIB
or IV NSCLC. Secondary objectives of the study included
overall and progression-free survival. This is the first evaluation
of DHA-paclitaxel in patients with advanced NSCLC.
PATIENTS AND METHODS
Patient Selection
Adult patients with NSCLC and measurable disease on
computed tomography (CT) were considered for this study.
Inclusion criteria included histologic or cytologic confirma-
tion of NSCLC, stage IIIB or IV disease, performance status
0 or 1 on the Eastern Cooperative Oncology Group scale, and
adequate baseline organ function (absolute neutrophil count
1500/mm3, platelet count 100,000/mm3, bilirubin 1.5
times the upper limit of normal, transaminases 2.5 times
upper limit of normal, creatinine 1.5 times upper limit of
normal). Patients were excluded if they were known to have
cerebral metastases, peripheral neuropathy (higher than grade
I) or other clinically significant medical conditions. Addition-
ally, patients who had received previous chemotherapy or had
an active infection were not eligible. Patients who had re-
ceived previous radiotherapy were included if their assessable
disease was outside the field of radiation. Written informed
consent had to be obtained from all patients before enrollment.
The study was conducted with the approval of the research
ethics committee at each participating center and performed
according to the standards of Good Clinical Practice.
Treatment
Following prophylactic administration of standard an-
tiallergic medication (dexamethasone, chlorpheniramine, and
an H2 blocker) used before taxane therapy, DHA-paclitaxel
was infused over 2 hours via peripheral venous access at a
starting dose of 1100 mg/m2 with no dose escalation. Treat-
ment cycles were repeated every 21 days until progression of
disease, unacceptable toxicity, refusal of continued treatment,
or investigator decision. The initial choice of starting dose of
1100 mg/m2 (molar equivalent of 803 mg/m2 of paclitaxel)
every 3 weeks was based on the results of a phase I study
involving 24 patients treated for a total of 78 courses of
therapy over five dose levels.23 The starting dose was reduced
to 900 mg/m2 (molar equivalent of 657 mg/m2 of paclitaxel)
based on toxicity among the first 13 patients treated. Pallia-
tive and supportive care for disease related symptoms was
offered to all participants.
Treatment Modifications
Toxicity was graded according to the National Cancer
Institute Common Toxicity Criteria (version 2.0, 1999),24 and
adjustments to the dose of DHA-paclitaxel were based on the
findings of previous courses. Treatment was delayed by 1
week if at day 22, neutrophil count was 1500/mm3 or
platelet count was 100,000/mm3. Colony-stimulating fac-
tors were not routinely administered. Treatment was delayed
for any nonhematologic toxicity of grade II or III present on
the day when DHA-paclitaxel would have been due. Any
nonhematologic grade IV toxicity led to immediate with-
drawal from the trial. Subsequent cycles of DHA-paclitaxel
after a delay were dose-reduced initially to 700 mg/m2 and
then to 500 mg/m2 for patients treated at an initial dose of 900
mg/m2. The dose was not reduced further. If patients were
delayed for 2 weeks, they were removed from the study.
Tumor Response
Measurable disease sites were assessed before entering
the study by physical examination, plain radiography, and
computed tomography of the thorax and abdomen. The pri-
mary efficacy parameter for this study was objective tumor
response. Therefore, tumor measurements and computed to-
mography were repeated after every two cycles and objective
tumor response determined according to RECIST (Response
Evaluation Criteria in Solid Tumors) criteria.25 Time to pro-
gression was defined as the time from recruitment to first
documentation of progressive disease.
Statistical Methods
For evaluation of efficacy, this study was designed
according to the Simon’s two-stage optimal design26 with a
target activity level of 25% and a lower activity level of 10%.
The type I error was set to 0.05, and the power was set to
80%. The first stage of patient enrollment was planned to be
18 assessable patients with a second stage of enrollment up to
a maximum of 44 patients. However, this design was modi-
fied after recruitment of 13 patients as described earlier. To
be considered assessable for response, patients had to com-
plete at least two courses of treatment and have at least one
post-treatment disease assessment performed. Survival data
according to Kaplan-Meier are presented for all eligible
patients recruited. Tumor response rate was also calculated
on an intent-to-treat basis.
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RESULTS
Patient Characteristics
Forty-four patients were recruited for this study from
four centers in the United Kingdom. The characteristics of the
44 enrolled patients are listed in Table 1. The study included
66% males, with a median age of 61.5 years (range, 39–74)
and baseline World Health Organization performance status
of 0 in 11 (25%). All patients treated met the trial entry
criteria. More than half the patients (55%) had stage IV
disease. Three patients (7%) had had previous radiotherapy
for NSCLC. Six patients (17%) had pleural effusions on entry
to the trial.
Toxicity
All 44 patients received at least one infusion of DHA-
paclitaxel and were considered assessable for toxicity. Sixty-
six percent of patients experienced grade III or IV toxicity.
Hematologic Toxicity
The dose-limiting toxicity was myelosuppression. Neu-
tropenia was the main hematologic toxicity identified. In
total, 31 patients experienced grade III or IV neutropenia
(84%) including 10 of 13 patients (77%) treated at the higher
starting dose of 1100 mg/m2. Grade III or IV neutropenia
occurred after 66 courses (48%) of treatment. This was
associated with fever or sepsis on 10 occasions (7% of cycles
administered) of which six were grade III and four were grade
IV. One patient developed grade III anemia and one patient
grade III thrombocytopenia. No other grade IV marrow
toxicity was observed. This is summarized in Table 2.
Nonhematologic Toxicity
Hypersensitivity reactions were the most serious non-
hematologic toxicity. A total of five (11%) patients experi-
enced hypersensitivity reactions. Three of these were grade
III and one was grade IV. All but one occurred on the first day
of the second cycle of treatment. No other grade III or IV
nonhematologic toxicity was observed. Neuropathy was the
most frequent nonhematologic toxicity. Four patients (9%)
developed grade II neuropathy and a further 10 (23%) expe-
rienced grade I neuropathy. Grade I alopecia affected only
four (9%) patients.
Toxic Death
One patient died while participating in the trial. Death
occurred 9 days after the patient received the second cycle of
DHA-paclitaxel (at a dose of 1100 mg/m2). The cause of
death was respiratory failure secondary to bilateral broncho-
pneumonia. The patient had grade III neutropenia at the point
of emergency admission 3 days earlier.
Dose Administration
Patients received between one and seven cycles of
treatment during the study. Thirteen patients commenced at a
starting dose of 1100 mg/m2 of DHA-paclitaxel and 31 at 900
mg/m2. Twenty-eight courses (mean, 2.1) were administered
in the 1100-mg/m2 cohort and 109 courses (mean, 3.5) in the
900-mg/m2 cohort. Mean duration on study was 69 days
(range, 9–161 days). Dose reductions were required in three
of the patients starting at 1100 mg/m2 and in five of the
patients starting at 900 mg/m2. The median number of treat-
ment cycles delivered was two (range one to seven, Table 3)
and the mean delivered dose was 911.8 mg/m2. The main
reason for treatment discontinuation was neutropenia. Four
patients did not complete two cycles of treatment. The reasons
for this were cerebrovascular accident (one patient), hypersen-
sitivity reaction (one patient), death (one patient described pre-
viously), and investigator decision (one patient).
Tumor Response
Forty (90%) patients completed at least two cycles of
treatment and were therefore assessable for tumor response.
One partial response was observed in the first 18 patients and
a further six in this group achieved stable disease. Overall,
partial responses were achieved in two (5%) patients and
stable disease in 16 (40%). Both responding patients were
treated with 900 mg/m2 of DHA-paclitaxel (Table 4). This
TABLE 1. Patient and Tumor Characteristics
Characteristics No. of Patients
Male/female 29/15
Median age, yr (range) 61 (39–74)
ECOG performance status
0 11
1 33
Stage IIIB/IV 20/24
Previous radiotherapy 3
TABLE 3. DHA-paclitaxel Administration
Mean Median Range
Days on study 69.0 47.5 9–161
Courses of treatment 3.1 2.0 1–7
TABLE 4. Best response to Treatment in Eligible Patient
population (n  40)
Disease Response No. (%) of Patients
Complete response 0 (0)
Partial response 2 (5)
Stable disease 16 (40)
Disease progression 22 (55)
TABLE 2. Grade III/IV Hematologic Toxicity
NCICTC Grade III/IV Toxicity No. of Patients (%)
Neutropenia 31 (70.5)
Neutropenia with pyrexia/sepsis 10 (22.7)
Thrombocytopenia 1 (2.3)
Anemia 1 (2.3)
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equates to a partial response rate of 4.5% and a 36.4% rate of
stable disease based on an intent-to-treat analysis (n  44).
Survival
Progression-free survival for all 44 patients was 44
days (95% confidence interval [CI]: 36–77 days) (Figure 1).
At the time of this analysis, four of the 44 patients were alive.
The median duration of survival, shown in Figure 2, for all
patients was 243 days (95% CI: 154–359 days) (Figure 2).
The median survival for patients treated at a starting dose of
1100 mg/m2 was 161 days (95% CI: 93–392 days) and the
median survival for patients treated at a starting dose of 900
mg/m2 was 299 days (95% CI: 193–384 days). The 1-year
survival rate was 35% and the 2-year survival rate was 15%
(Table 5). There was no significant difference in survival
between the two cohorts based on a log-rank test (Table 5).
DISCUSSION
This study is the first phase II trial of DHA-paclitaxel as
first-line palliative treatment for chemotherapy-naı¨ve patients
with locally advanced (stage IIIB) and metastatic (stage IV)
NSCLC. The primary aim of the study was to assess the
antitumor activity and toxicity of this novel agent. Secondary
objectives were to examine progression-free survival and
survival after treatment with DHA-paclitaxel when adminis-
tered once every 3 weeks. The starting dose of 1100 mg/m2
was derived from phase I clinical trials with DHA-paclitax-
el.23 Our patient group was unable to tolerate this dose,
experiencing toxicity that was both unacceptable and unpre-
dictable. The dose of DHA-paclitaxel was therefore reduced
to 900 mg/m2 for the remainder of the study (31 patients).
The objective tumor response rate of 4.5% was disap-
pointing and did not meet the study goal of a 10% response
rate. Thus, we conclude that DHA-paclitaxel should be re-
jected as a realistic treatment option for the treatment of
locally advanced and metastatic NSCLC. Survival was a
secondary endpoint of this small phase II study and is likely
to have been influenced by additional therapies. There is no
suggestion of any survival advantage after the use of DHA-
FIGURE 1. Progression-free sur-
vival (n  44; median time to dis-
ease progression  44 days).
FIGURE 2. Kaplan-Meier overall
survival analysis (n  44; median
survival  243 days).
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paclitaxel over the use of standard platinum-based combina-
tion chemotherapy in this selected group of patients. How-
ever, the median survival of 299 days (95% CI: 193–384
days) observed in the group treated at a starting dose of
900 mg/m2 is comparable to survival anticipated for the
same patients treated with conventional platinum doublet
regimens.7
Current first-line chemotherapy for inoperable NSCLC
remains inadequate. Evidence supports the use of platinum-
containing chemotherapy regimens, and published guidelines
recommend this,27,28 particularly for patients with a good
performance status. The survival benefit conferred by che-
motherapy is modest (typically10 weeks). Patients with the
diagnosis of advanced NSCLC are frequently elderly and
frail, with up to 40% being older than age 70 at diagnosis.2
Comorbidities often necessitate cautious selection of appro-
priate therapies and minimal use of nephrotoxic platinum
agents. Advanced NSCLC is often associated with significant
disease-related symptoms. Maintaining quality of life is an
important goal of medical management. Objective evidence
of symptomatic improvement following treatment remains an
important palliative endpoint. Ongoing research into effective
novel agents, particularly single agents of low toxicity that
can be given on an outpatient basis, is therefore vital.
There is evidence supporting the use of taxanes in
NSCLC, with studies confirming antitumor activity both in
previously untreated patients13–15,29 and in patients who have
failed previous platinum-based chemotherapy.16 First-line re-
sponse rates of up to 38% have been reported after the use of
single-agent taxanes in advanced NSCLC.12–15 However, the
emergence of drug resistance and the occurrence of unaccept-
able toxicities such as peripheral neuropathy may limit their
clinical value. The aim of this study was to develop a novel
agent that improves the therapeutic efficacy of standard taxanes.
Phase I clinical testing suggested an encouraging tox-
icity profile for DHA-paclitaxel in humans.23 No alopecia and
no peripheral neuropathy greater than grade I were observed
at any dose despite the fact that these are typical toxicities
associated with the use of other taxanes. Mucositis also
occurred less frequently than is reported with both paclitaxel
and docetaxel. Myelosuppression was the principal toxicity.
Grade III/IV neutropenia occurred in 100% of patients re-
ceiving DHA-paclitaxel at a dose of 1100 mg/m2 (74% of
courses). However, marrow function recovered within the
21-day cycle and no cycles of therapy were delayed because
of persistent myelosuppression.21
Conventional taxanes are known to cause significant
side effects. This includes a 40% to 44% incidence of grade
III/IV neutropenia at a standard docetaxel dose of 75 mg/m2
every 21 days30,31 and at least a 30% incidence of hypersen-
sitivity reactions if appropriate premedication is not admin-
istered.32,33 Although the trial that we report is small, 84% of
patients experienced grade III or IV neutropenia and this
degree of neutropenia was documented in 48% of courses of
treatment administered. In the group of patients treated at the
lower starting dose, 68% experienced grade III or IV neutro-
penia. This would suggest that these dose levels of DHA-
paclitaxel are associated with a greater incidence of myelo-
suppression than conventional taxanes in patients with
advanced NSCLC, and this has significant implications for its
clinical application. However, nonhematologic toxicity was
generally mild and more favorable when compared with
conventional taxanes.
DHA-paclitaxel is a novel agent for the treatment of
NSCLC. Preclinical studies suggest that conjugation of DHA
to a taxane enhances intratumoral drug concentration. It was
hoped that in clinical settings, this would translate into an
improved therapeutic index when compared to standard tax-
anes. In this study, the objective tumor response rate was
disappointingly low (4.5%). Although patient survival ap-
peared to be broadly comparable to that with other known
active agents, myelosuppression was more frequently associ-
ated with DHA-paclitaxel than has been reported for other
taxanes in this setting. Although response rates can be quite
variable in phase II/III studies in advanced NSCLC, the
further development of DHA-paclitaxel would likely require
either further dose reduction or the use of prophylactic
granulocyte colony–stimulating factor.
The results reported here should be put into context
with contemporaneous studies examining other novel thera-
pies for the treatment of NSCLC. These include both classic
cytotoxic drugs and biological therapies. The novel multitar-
geted antifolate pemetrexed has both phase II and III data
suggesting activity in NSCLC. Response rates of 20% to 40%
have been reported for the use of pemetrexed as first-line
therapy either alone34 or in combination with cisplatin.35,36
Pemetrexed may also have a role as second-line treatment for
NSCLC.31
Many phase II and III trials of biological response-
modifying agents have been reported in this disease. These
include encouraging studies of the use of the oral epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
gefitinib37,38 and erlotinib in selected patients39 40,41 and trials
of bevacizumab, a monoclonal antibody targeting the vascu-
lar endothelial growth factor receptor, administered in com-
bination with conventional chemotherapy.42,43 Phase II trials
of the humanized monoclonal antibody trastuzumab have
focused on combination therapy with classic cytotoxics, and
therefore interpretation of the contribution of the novel agent
to the reported response rates is difficult.44 There are no data
supporting a role for single-agent trastuzumab. Other phase II
studies of novel agents for NSCLC in the past few years have
been disappointing, often with no objective responses observed.
These include nonrandomized studies of the farnesyl transferase
TABLE 5. Survival Data
Dose (mg/m2)
Survival
Median
Survival (days)
95% CI % Survival
Lower Upper 1 year 2 year
900 299 193 384 36 14
1100 161 93 392 31 16
All 243 154 359 35 15
CI, confidence interval.
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inhibitor tipifarnib,45 the dolastatin analogue LU 103793,46 and
the cyclin-dependent kinase inhibitor flavopiridol.47
Management of NSCLC remains suboptimal. Much work
has gone into comparing different combinations of standard
therapies and optimizing the chemotherapy schedules available.
Despite numerous comparative studies, no single regimen has
emerged that is superior to others. It seems likely that significant
future advances in the management of this common disease will
come only from the development of novel agents. Recent en-
couraging results, particularly with novel biological therapies,
have led to renewed optimism in this challenging field.
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